下腔静脉滤器在下肢深静脉血栓治疗中的临床应用

目的 探讨下腔静脉滤器植入在下肢深静脉血栓治疗中预防肺动脉栓塞的应用价值。方法 30例下肢深静脉血栓形成的病人，14例植入永久性腔静脉滤器．16例植入临时性腔静脉滤器；27例分别行单纯静脉溶栓或切开取栓＋静脉置管溶栓；全部病例同时行抗凝治疗。结果 下腔静脉滤器植入全部成功，症状体征完全消失7例，明显缓解18例，部分缓解5例。滤器植入期间未发生肺栓塞。临时滤器在体内留置时间26～40d，1例取出后2d出现复发性肺栓塞；2例永久性滤器植入者于6个月和14个月出现下腔静脉堵塞。结论 下腔静脉滤器植入术是一种安全、有效预防肺动脉栓塞发生的临床措施，临时性和永久性滤器各有优缺点。     

下腔静脉滤器植入术在防治肺动脉栓塞中的应用

目的 探讨下腔静脉滤器植入术在防治肺动脉栓塞中的价值。方法 回顾性分析1998年8月—2003年6月间实施的61例下腔静脉滤器植入术防治肺动脉栓塞的临床资料。结果 临时性下腔静脉滤器植入11例，永久性下腔静脉滤器50例。随访3～66个月，平均38个月。61只下腔静脉滤器均展开良好，有1例临时滤器移位至下腔静脉近心端，其他无移位。临时滤器体内置放时间2～4周取出。1例永久性滤器植入14个月后滤器中血栓形成。均未再发生肺动脉栓塞。结论 下腔静脉滤器植入术确能有效预防肺动脉栓塞，但应严格掌握适应症。     

下腔静脉滤器植入预防肺动脉栓塞的临床应用

目的:探讨下腔静脉滤器植入预防下肢深静脉血栓形成中肺动脉栓塞的临床价值.方法:10例下肢深静脉血栓的患者进行下腔静脉滤器植入,并对疗效进行观察.结果:所有下腔静脉滤器植入和手术取栓都获得了成功,效果明显.无滤器发生移位,无肺动脉栓塞.结论:下腔静脉滤器植入是预防下肢深静脉血栓肺动脉栓塞可靠的方法.     

下腔静脉滤器植入预防肺动脉栓塞40例临床分析

目的探讨在下肢深静脉血栓形成病人中植入下腔静脉滤器预防肺动脉栓塞的效果及临床意义。方法分析自2008年8月至2009年10月我院40例下肢深静脉血栓形成病人植入下腔静脉滤器的患者。所有患者在滤器植入前均进行下肢静脉彩超检查,其中8例有症状性肺栓塞,1例出现呼吸心跳骤停,经积极抢救得以复苏,3例因某些原因不能进行抗凝和溶栓治疗,7例主动要求植入滤器。36例滤器由右股静脉穿刺植入,4例由右颈内静脉穿刺植入,所有滤器均植入右肾静脉水平以下1～1．5cm的下腔静脉内L2～L3间。结果40例患者下腔静脉内均成功植入滤器,均无严重手术并发症发生。36例随访6～14个月,滤器无移位。4例随访1年后失访。结论对于下肢深静脉血栓形成病人,下腔静脉滤器植入是预防肺动脉栓塞发生的安全、有效的方法。     

经颈静脉Aegisy腔静脉滤器在下肢DVT导管溶栓治疗中的临床应用

目的探讨Aegisy腔静脉滤器在下肢深静脉血栓形成（DVT）经导管溶栓治疗中的临床应用价值。方法2008年4月～2009年8月间,45例下肢DVT患者（左侧：36例,右侧：6例,双侧：3例,4例已发生肺栓塞）在经颈静脉插管溶栓过程中行Aegisy腔静脉滤器置入术,以防止肺动脉栓塞。结果45支Aegisy腔静脉滤器经颈静脉一次性于下腔静脉植入成功,技术成功率100%,术中未出现滤器错位、移位、倾斜、滤器折断、腔静脉穿孔、下腔静脉阻塞等并发症。在溶栓治疗过程中1例肺动脉栓塞患者因右心衰竭死亡,其他患者无症状性肺动脉栓塞发生。溶栓治疗后,45支滤器中的36只成功取出,滤器留置时间为7～18天（平均9.5天）,余9支滤器永久性留置于患者体内。随访2～17个月（平均9.7个月）,滤器无移位及血栓形成。结论Aegisy腔静脉滤器经颈静脉途径植入方法简单、释放可控、安全,可有效防止症状性肺动脉栓塞。     

困难可回收滤器成因分析及取出策略

目的 探讨困难可回收下腔静脉滤器形成原因及取出技巧。 方法 回顾性分析2017年1月—2018年10月期间浙江省台州医院收治的405例患者，其中单纯滤器植入组植入滤器232例,腔内组植入滤器173例。滤器植入组回收101例，腔内治疗组回收160例。2组共有30例滤器无法按常规方法回收，其中滤器植入组10例发生滤器倾斜、移位，2例滤器内捕获血栓；腔内治疗组17例发生滤器倾斜、移位，1例滤器内捕获血栓。对于滤器内捕获血栓的患者，采用置管溶栓辅助常规圈套技术法、导管吸栓辅助常规圈套技术取出法进行回收。对于滤器倾斜、贴壁的患者，采用导引导管辅助常规圈套技术法、圈套辅助硬导丝拉动钩端法等方法进行回收。 结果 针对滤器捕获血栓的3例，采用置管溶栓辅助常规圈套技术法取出1例，导管吸栓辅助常规圈套技术取出法取出2例。针对滤器倾斜、贴壁的27例，采用导引导管辅助常规圈套技术法取出24例，圈套辅助硬导丝拉动钩端法取出2例，另一例因滤器与下腔静脉壁广泛粘连，难以回收。30例困难滤器实际成功回收29例，成功率为96.7%。 结论 滤器倾斜、贴壁及捕获血栓是导致下腔静脉滤器难以取出的主要原因，采用多种辅助性圈套技术可以提高其回收率。      

下腔静脉临时滤器植入预防肺栓塞52例

目的：探讨下腔静脉临时滤器植入预防因下肢深静脉血栓（deep veinthrombosis,DVT）而引起肺动脉栓塞（pul monary embolism,PE）的应用价值。方法：回顾性分析我院临时滤器植入52例下肢DVT患者。结果：52例滤器均成功植入,1例未取出,51例取出,37例滤器捕获血栓,无症状性肺栓塞发生。结论：临时滤器植入预防因DVT而引起的PE安全有效。     

系统治疗下肢深静脉血栓形成1455例临床分析

目的探讨下肢深静脉血栓形成（DVT）的有效治疗方法。方法回顾性分析1993年1月-2008年11月间治疗的1455例下肢DVT的临床资料,直接患肢深静脉溶栓1379例,其中下腔静脉滤器植入22例（临时性滤器6例,永久性滤器16例）。下腔静脉植入并手术治疗76例（取栓、球囊扩张、支架植入、髂静脉成型）,其中下腔静脉植入临时性滤器5例,永久性滤器61例。结果随访3个月～15年,溶栓组显效705例,有效648例,无效26例。手术组显效67例,有效7例,无效2例。手术组显效率显著高于溶栓组（P〈0.05）,但总有效率差别无显著性（P〉0.05）。肺拴塞死亡18例。98支下腔静脉滤器均展开良好,有2例临时滤器移位至下腔静脉近心端,其他无移位。临时滤器体内置放2周～4周取出,8例永久性滤器植入14个月后滤器中发现血栓形成并机化。结论下腔静脉滤器植入能有效预防肺动脉栓塞,但应严格掌握适应证,手术综合治疗是提高疗效和预防下肢DVT后遗症的有效方法。     

下腔静脉滤器置入预防肺栓塞的临床观察

目的探讨下腔静脉滤器置入术对下肢深静脉血栓形成后引起肺栓塞的预防效果。方法7例下肢静脉血栓形成患者采用Seldinger技术施行下腔静脉滤器置入术。结果滤器全部安全置入肾静脉下方的下腔静脉内。随访3个月～22个月,6例无肺栓塞的患者,无肺栓塞发生,滤器无移位,1例已有肺栓塞者症状明显减轻。结论下腔静脉滤器用于预防肺动脉栓塞是一种安全有效的方法。     

下腔静脉滤器置入预防肺栓塞的临床观察

目的 探讨下腔静脉滤器置入木对下肢深静脉血栓形成后引起肺栓塞的预防效果。方法 7例下肢静脉血栓形成患者采用Seldinger技术施行下腔静脉滤器置入术。结果滤器全部安全置入肾静脉下方的下腔静脉内。随访3个月～22个月，6例无肺栓塞的患者，无肺栓塞发生，滤器无移位，1例已有肺栓塞者症状明显减轻。结论 下腔静脉滤器用于预防肺动脉栓塞是一种安全有效的方法。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…